Cite
HARVARD Citation
Korde, N. et al. (2021). Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twice‐weekly carfilzomib (45 and 56 mg/m2) in combination with lenalidomide and dexamethasone. American journal of hematology. 96 (6), pp. E193-E196. [Online].